DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $2.25B
• Dividend Yield: 5.67%
• Average Volume (3M): 3.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: -7.08%
• EPS Growth: -113.81%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.37
• Shares Outstanding: 199,551,970
• 10 Day Avg. Volume: 4,078,962
• 30 Day Avg. Volume: 3,749,902
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 13.73
• Enterprise Value/Market Cap: 2.06
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 2.52
• Enterprise Value/Ebitda: -10.76
• 1Y Price Target: $13.42
• Price Target Upside: 18.34% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 15
• EPS Forecast (FY): 1.65
• Revenue Forecast (FY): $3.65B

• Rating: 42 Neutral
• Price Target: $10.50 ▼(-7.41% Downside)

DENTSPLY SIRONA's overall stock score reflects significant financial and technical challenges. The company's financial performance is weak, with declining revenues, negative profitability, and liquidity issues. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold indicators. The valuation is also concerning, with a negative P/E ratio, although the high dividend yield provides some appeal. The company's strategic challenges and focus on a turnaround plan add to the uncertainty.

Positive Factors

European Sales Growth

Growth in European sales, particularly in Connected Technology Solutions, indicates strong market presence and potential for further expansion in this region.

Wellspect Healthcare

Wellspect Healthcare's growth across all regions highlights its strategic importance and potential to drive future revenue and profitability.

Return to Shareholders

Consistent dividend payments reflect a commitment to shareholder returns, which can enhance investor confidence and support stock stability.

Negative Factors

Decline in Global Sales

A decline in global sales, particularly in the U.S., signals challenges in maintaining market share and revenue growth, impacting long-term prospects.

Impairment Charge

Significant impairment charges indicate potential overvaluation of assets and can strain financial resources, affecting future profitability.

Adjusted EPS Decline

A decline in adjusted EPS reflects operational challenges and could hinder the company's ability to reinvest in growth and innovation.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA (XRAY) is a leading global manufacturer of dental products and technologies, specializing in digital imaging solutions, including X-ray systems. The company operates primarily in the dental sector, providing a wide range of products that enhance dental care and treatment. DENTSPLY SIRONA's core offerings include dental imaging equipment, CAD/CAM systems, dental consumables, and equipment for restorative, preventive, and orthodontic procedures, serving dental professionals and laboratories worldwide.

How the Company Makes Money

DENTSPLY SIRONA generates revenue through multiple streams, primarily from the sale of dental equipment and consumables. Their core revenue comes from the manufacturing and distribution of dental imaging systems, including X-ray machines and digital imaging software, which are sold to dental practices and clinics. Additional revenue is derived from dental materials and supplies, such as restorative materials and orthodontic products. The company also benefits from recurring revenue through the sale of maintenance services and software upgrades for their imaging systems. Strategic partnerships with dental professionals, educational institutions, and other healthcare providers enhance their distribution network and market presence, contributing to their overall earnings. The company's commitment to innovation and product development further positions it to capitalize on emerging trends in dental technology, thereby expanding its revenue potential.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA is experiencing significant financial challenges with declining revenue, negative profitability, increased leverage, and weakened cash flow. The company needs to address operational inefficiencies and improve financial stability to enhance its financial health.

Income Statement

DENTSPLY SIRONA has faced declining revenue and profitability, with a negative net profit margin of -25.85% in TTM. The gross profit margin remains moderate at 51.68%, but the company struggles with negative EBIT and EBITDA margins, indicating operational challenges. Revenue growth has been negative, highlighting a need for strategic improvements.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.27 in TTM, indicating higher leverage. Return on equity is negative, reflecting losses. However, the equity ratio remains reasonable, suggesting some stability in asset management. The balance sheet shows potential risk due to increased debt levels.

Cash Flow

Operating cash flow is positive but has decreased, with a coverage ratio of 0.24 in TTM. Free cash flow has declined significantly, with a growth rate of -50.36%. The free cash flow to net income ratio is positive, but overall cash flow performance indicates financial strain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.62B	3.79B	3.96B	3.92B	4.23B	3.34B
Gross Profit	1.84B	1.96B	2.09B	2.13B	2.35B	1.66B
EBITDA	-432.00M	-518.00M	249.00M	-662.00M	952.00M	330.00M
Net Income	-882.00M	-910.00M	-132.00M	-950.00M	411.00M	-73.00M
Balance Sheet
Total Assets	5.65B	5.75B	7.37B	7.64B	9.24B	9.35B
Cash, Cash Equivalents and Short-Term Investments	363.00M	272.00M	334.00M	365.00M	339.00M	438.00M
Total Debt	2.48B	2.27B	2.30B	2.15B	2.29B	2.46B
Total Liabilities	4.17B	3.81B	4.08B	3.83B	4.24B	4.42B
Stockholders Equity	1.48B	1.94B	3.29B	3.81B	5.00B	4.93B
Cash Flow
Free Cash Flow	80.00M	281.00M	228.00M	368.00M	515.00M	562.00M
Operating Cash Flow	221.00M	461.00M	377.00M	517.00M	657.00M	649.00M
Investing Cash Flow	-144.00M	-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
Financing Cash Flow	-19.00M	-302.00M	-307.00M	-329.00M	-379.00M	476.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Neutral. The current price of 11.34 is above the 20-day moving average (MA) of 11.18, below the 50-day MA of 12.11, and below the 200-day MA of 14.23, indicating a neutral trend. The MACD of -0.48 indicates Negative momentum. The RSI at 48.36 is Neutral, neither overbought nor oversold. The STOCH value of 84.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COO	75 Outperform	$15.50B	38.37	5.01%	―	6.35%	12.94%
RMD	71 Outperform	$37.23B	26.10	25.41%	0.88%	9.36%	29.56%
HOLX	69 Neutral	$16.67B	30.12	11.12%	―	1.74%	-25.29%
BDX	64 Neutral	$55.34B	33.34	6.54%	2.35%	8.23%	-2.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XRAY	42 Neutral	$2.25B	―	-44.44%	5.67%	-7.08%	-113.81%
BAX	40 Neutral	$9.72B	―	-4.70%	2.77%	-21.20%	-325.40%

DENTSPLY SIRONA Corporate Events

Dentsply Sirona Unveils Strategic Plan Amid Q3 Losses

Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, is renowned for its innovative solutions that advance patient care and enhance dental services globally. The company, headquartered in Charlotte, North Carolina, operates in the dental and medical device sectors, offering a comprehensive range of dental and oral health products.

DENTSPLY SIRONA Faces Challenges Amid Earnings Call Insights

DENTSPLY SIRONA’s recent earnings call painted a challenging picture, marked by a decline in global and U.S. sales, an impairment charge, and a drop in EPS. Despite some positive developments, such as growth in European sales and Wellspect Healthcare, the overall sentiment was negative due to the financial difficulties and strategic hurdles the company faces. The focus was on a turnaround strategy to navigate these pressing issues.

DENTSPLY SIRONA CFO Matthew Garth Steps Down

On October 31, 2025, DENTSPLY SIRONA Inc. announced that Matthew E. Garth will step down from his role as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun searching for a new CFO and clarified that Garth’s departure is not due to any disagreements regarding the company’s financial practices. Concurrently, Daniel T. Scavilla, the company’s President and CEO, will take on the additional role of interim principal financial officer. This transition is not expected to involve any new compensatory arrangements for Scavilla.

The most recent analyst rating on (XRAY) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA SEC Investigation Concludes Favorably

On October 14, 2025, DENTSPLY SIRONA announced that the SEC has concluded its investigation, which began in May 2022, into the company’s financial reporting matters without recommending any enforcement action. This closure is seen as a significant and favorable development for the company, reflecting its cooperation with the SEC and potentially strengthening its position in the industry.

The most recent analyst rating on (XRAY) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Announces Leadership Transition for Rosenzweig

On October 2, 2025, DENTSPLY SIRONA announced that Richard C. Rosenzweig will transition from his role as Executive Vice President, Corporate Development, General Counsel, and Secretary to a non-executive position as Special Legal Advisor, effective October 3, 2025. This transition is part of a mutual agreement, and Mr. Rosenzweig will continue to serve in an advisory capacity until March 4, 2026, with a monthly fee and additional severance benefits, before becoming an independent contractor consultant for a year.

The most recent analyst rating on (XRAY) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Approves Retention Award for Executives

On September 19, 2025, DENTSPLY SIRONA‘s Board approved a one-time retention equity incentive award for executives, including Tony Johnson, to recognize his performance during a leadership transition. The award, valued at $2 million in stock options, aims to retain Johnson for three years, with options vesting on the third anniversary and expiring ten years from the grant date.

The most recent analyst rating on (XRAY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona Retains Wellspect Healthcare After Review

On September 8, 2025, Dentsply Sirona announced the completion of its strategic review of the Wellspect Healthcare business, deciding to retain it within its portfolio. This decision follows extensive evaluation and outreach, concluding that Wellspect, a leader in the global continence care market, will deliver greater financial and strategic benefits to stockholders as part of Dentsply Sirona, given its strong product pipeline and market potential.

The most recent analyst rating on (XRAY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Faces Challenges Amid Growth Opportunities

DENTSPLY SIRONA’s latest earnings call reflected a challenging quarter marked by declines in sales across several regions and segments, particularly in the U.S. and CTS segment. Despite these hurdles, there were areas of stability and growth, such as the DS Core platform and Germany’s sales performance. However, the significant impact of tariffs and impairment charges weighed heavily on the overall sentiment.